Can you take Benzethonium chloride / lidocaine topical with Cyclophosphamide?

cycloPHOSphamide has a major potential interaction with Bladder Infection.

The use of cyclophosphamide is contraindicated in patients with urinary outflow obstruction. Urinary tract obstruction should be excluded or corrected before treatment because cyclophosphamide can cause urotoxicity, which may be fatal.

cycloPHOSphamide has a major potential interaction with Bleeding Disorder.

Cyclophosphamide should not be administered to patients with neutrophil counts of 1,500/mm3 or less and platelet counts below 50,000/mm3. Cyclophosphamide can cause myelosuppression, bone marrow failure, and severe immunosuppression; complete blood counts should be monitored during treatment.

cycloPHOSphamide has a major potential interaction with Bone Marrow Depression/Low Blood Counts.

Cyclophosphamide should not be administered to patients with neutrophil counts of 1,500/mm3 or less and platelet counts below 50,000/mm3. Cyclophosphamide can cause myelosuppression, bone marrow failure, and severe immunosuppression; complete blood counts should be monitored during treatment.

cycloPHOSphamide has a moderate potential interaction with Fever.

Cyclophosphamide treatment may not be indicated, or may require interruption or dose reduction, in patients with a serious infection. Cyclophosphamide can cause severe immunosuppression and reactivate latent infections; it should be used with caution, if at all, in patients with active urinary tract infections.

The lidocaine topical in benzethonium chloride / lidocaine topical has a major potential interaction with Heart Block.

Lidocaine is absorbed through intact skin and mucosal membranes following topical administration. Prolonged exposure, large doses, frequent applications and/or use on compromised skin or mucosa can produce systemic effects. At high plasma levels, lidocaine can cause hypotension, bradycardia, and cardiovascular collapse. Therapy with lidocaine topical should be administered cautiously in patients with shock, sinus bradyarrhythmia, or severe heart block. The recommended dosage should not be exceeded. Children and debilitated, elderly, or acutely ill patients should be given reduced dosages commensurate with their age, weight, and physical condition.

cycloPHOSphamide has a moderate potential interaction with Heart Disease.

Cyclophosphamide can cause myocarditis, myopericarditis, pericardial effusion, arrhythmias, and congestive heart failure, which may be fatal. Particular caution is necessary in patients with pre-existing cardiac disease; monitor these patients for cardiotoxicity.

cycloPHOSphamide has a moderate potential interaction with History, Radiation Therapy.

Previous radiation treatment to the cardiac region may increase the risk of cyclophosphamide cardiotoxicity, and previous abdominal radiation is a risk factor for cyclophosphamide-associated veno-occlusive liver disease. Patients with risk factors for cardiotoxicity should be monitored during treatment.

cycloPHOSphamide has a moderate potential interaction with Infection.

Cyclophosphamide treatment may not be indicated, or may require interruption or dose reduction, in patients with a serious infection. Cyclophosphamide can cause severe immunosuppression and reactivate latent infections; it should be used with caution, if at all, in patients with active urinary tract infections.

The lidocaine topical in benzethonium chloride / lidocaine topical has a major potential interaction with Liver Disease.

Lidocaine topical is absorbed through intact skin and mucosal membranes. Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of lidocaine. Lidocaine is rapidly and extensively metabolized by the liver. Less than 10% is eliminated unchanged in the urine. Several inactive and two active forms (MEGX and GX) have been identified. MEGX and GX exhibit antiarrhythmic and convulsant properties. The pharmacokinetic disposition of lidocaine is altered by changes in hepatic function, including hepatic blood flow. Therapy with lidocaine topical should be administered cautiously and dosing modified for patients with compromised hepatic function.

cycloPHOSphamide has a moderate potential interaction with Liver Disease.

Pre-existing disturbances of hepatic function are a risk factor for cyclophosphamide-associated veno-occlusive liver disease, which can be fatal. Severe hepatic impairment may reduce conversion of cyclophosphamide to its active metabolite, potentially reducing efficacy.

cycloPHOSphamide has a moderate potential interaction with Pulmonary Impairment.

Pneumonitis, pulmonary fibrosis, pulmonary veno-occlusive disease and other forms of pulmonary toxicity leading to respiratory failure have been reported during and following treatment with cyclophosphamide. Pneumonitis may develop years after treatment with cyclophosphamide. Patients should be monitored for signs and symptoms of pulmonary toxicity. Caution is advised in patients with preexisting pulmonary impairment.

The lidocaine topical in benzethonium chloride / lidocaine topical has a major potential interaction with Renal Dysfunction.

Lidocaine topical is absorbed through intact skin and mucosal membranes. Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of lidocaine. Lidocaine is primarily eliminated by the kidney. Less than 10% is eliminated unchanged in the urine. Two active metabolites (MEGX and GX) have been identified that exhibit antiarrhythmic and convulsant properties. Serum concentrations of lidocaine and the active metabolites are increased and the half-life prolonged in patients with renal impairment. Therapy with lidocaine topical should be administered cautiously and dosing modified for repeated doses in patients with compromised renal function.

cycloPHOSphamide has a moderate potential interaction with Renal Dysfunction.

In patients with severe renal impairment, decreased renal excretion may result in increased plasma levels of cyclophosphamide and its metabolites, which may result in increased toxicity. Monitor patients with severe renal impairment (CrCl =10 mL/min to 24 mL/min) for signs and symptoms of toxicity. Therapy with cyclophosphamide should be administered cautiously in patients with a history of or predisposition to renal dysfunction. Clinical monitoring of renal function is recommended.

The lidocaine topical in benzethonium chloride / lidocaine topical has a major potential interaction with Seizures.

Lidocaine topical is absorbed through intact skin and mucosal membranes. Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of lidocaine. Seizures can occur as a result of accumulation of active metabolites. Therapy with lidocaine topical should be administered cautiously to patients with or predisposed to seizure disorders.

The lidocaine topical in benzethonium chloride / lidocaine topical has a major potential interaction with Shock.

Lidocaine is absorbed through intact skin and mucosal membranes following topical administration. Prolonged exposure, large doses, frequent applications and/or use on compromised skin or mucosa can produce systemic effects. At high plasma levels, lidocaine can cause hypotension, bradycardia, and cardiovascular collapse. Therapy with lidocaine topical should be administered cautiously in patients with shock, sinus bradyarrhythmia, or severe heart block. The recommended dosage should not be exceeded. Children and debilitated, elderly, or acutely ill patients should be given reduced dosages commensurate with their age, weight, and physical condition.

The lidocaine topical in benzethonium chloride / lidocaine topical has a major potential interaction with Teething Syndrome.

Topical lidocaine is not recommended to be used in teething infants and young children, as its ingestion is dangerous and potentially fatal. Ingestion of the drug has shown to result in seizures, severe brain injury, and heart problems in children.

cycloPHOSphamide has a major potential interaction with Urinary Tract Infection.

The use of cyclophosphamide is contraindicated in patients with urinary outflow obstruction. Urinary tract obstruction should be excluded or corrected before treatment because cyclophosphamide can cause urotoxicity, which may be fatal.

cycloPHOSphamide has a major potential interaction with Urinary Tract Obstruction.

The use of cyclophosphamide is contraindicated in patients with urinary outflow obstruction. Urinary tract obstruction should be excluded or corrected before treatment because cyclophosphamide can cause urotoxicity, which may be fatal.